JP2023536630A5 - - Google Patents

Info

Publication number
JP2023536630A5
JP2023536630A5 JP2023507633A JP2023507633A JP2023536630A5 JP 2023536630 A5 JP2023536630 A5 JP 2023536630A5 JP 2023507633 A JP2023507633 A JP 2023507633A JP 2023507633 A JP2023507633 A JP 2023507633A JP 2023536630 A5 JP2023536630 A5 JP 2023536630A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507633A
Other languages
English (en)
Japanese (ja)
Other versions
JP7854423B2 (ja
JP2023536630A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044330 external-priority patent/WO2022031695A1/en
Publication of JP2023536630A publication Critical patent/JP2023536630A/ja
Publication of JP2023536630A5 publication Critical patent/JP2023536630A5/ja
Application granted granted Critical
Publication of JP7854423B2 publication Critical patent/JP7854423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507633A 2020-08-04 2021-08-03 Pd-l1結合性作用剤およびその使用 Active JP7854423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061109P 2020-08-04 2020-08-04
US63/061,109 2020-08-04
PCT/US2021/044330 WO2022031695A1 (en) 2020-08-04 2021-08-03 Pd-l1 binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2023536630A JP2023536630A (ja) 2023-08-28
JP2023536630A5 true JP2023536630A5 (enExample) 2024-08-08
JP7854423B2 JP7854423B2 (ja) 2026-05-01

Family

ID=80118473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507633A Active JP7854423B2 (ja) 2020-08-04 2021-08-03 Pd-l1結合性作用剤およびその使用

Country Status (7)

Country Link
US (1) US20230303699A1 (enExample)
EP (1) EP4192884A4 (enExample)
JP (1) JP7854423B2 (enExample)
CN (1) CN116390951A (enExample)
AU (1) AU2021322183A1 (enExample)
CA (1) CA3187850A1 (enExample)
WO (1) WO2022031695A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192878A4 (en) * 2020-08-04 2025-04-16 Exelixis, Inc. Multi-specific binders and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362325B2 (en) * 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
EP2700651B1 (en) * 2008-07-18 2019-04-10 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
WO2013022848A1 (en) * 2011-08-05 2013-02-14 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
PE20170903A1 (es) * 2014-08-12 2017-07-12 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6
CA3007135A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
US20190106494A1 (en) * 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗pd-l1およびil-2サイトカイン
SMT202600123T1 (it) 2016-06-29 2026-05-12 Checkpoint Therapeutics Inc Anticorpi specifici per il pd-l1 e metodi di utilizzo degli stessi
PT3592769T (pt) 2017-03-09 2024-07-31 Genmab As Anticorpos contra pd-l1
SG10202110184XA (en) * 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof
MX2019012461A (es) 2017-04-18 2019-12-11 R Pharm Overseas Inc Anticuerpo anti-pd-l1 y uso del mismo.
EP3672634A1 (en) * 2017-08-24 2020-07-01 Invenra, Inc. Multivalent receptor-clustering agonist antibody constructs
SG11202003652QA (en) * 2017-10-27 2020-05-28 Univ New York Anti-galectin-9 antibodies and uses thereof
JP7383617B2 (ja) * 2017-12-28 2023-11-20 ナンジン レジェンド バイオテック カンパニー,リミテッド Pd-l1に対する抗体及びそのバリアント
CN112424225B (zh) 2018-03-29 2023-08-11 桂林三金药业股份有限公司 抗pd-l1抗体及其用途

Similar Documents

Publication Publication Date Title
JP7551693B2 (ja) NKp46結合タンパク質の可変領域
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
JP6606505B2 (ja) 抗SIRPα抗体および二重特異性マクロファージ増強抗体
JP2017535257A5 (enExample)
AU2019412754B2 (en) BTN3A binding proteins and uses thereof
CA3144324A1 (en) Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
JP2023549537A5 (enExample)
CN113874399A (zh) 抗ror1/抗cd3双特异性结合分子
CN114502591A (zh) 靶向bcma的抗体、双特异性抗体及其用途
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2023536631A5 (enExample)
JP2024532489A5 (enExample)
JP2017521054A5 (enExample)
IL305954A (en) Nectin-4 protein antibody and extacan compounds
JP2017507131A5 (enExample)
CN114641504A (zh) 抗b7h4抗体及其双抗和应用
JP2016501877A5 (enExample)
JP2025506143A5 (enExample)
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
CN115916816A (zh) 抗血清白蛋白抗体
JP2024517953A5 (enExample)
JP2022517216A5 (enExample)
TW202204424A (zh) 用於人類疾病之治療的cd38抗體
JP2025518493A5 (enExample)
JP2022502079A5 (enExample)